Notice: This company has been marked as potentially delisted and may not be actively trading. Jupiter Neurosciences (JUNS) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesTrends JUNS vs. ADAG, PLRX, BHST, LXRX, RGLS, ANL, RANI, ANIX, CRBP, and SLSShould you be buying Jupiter Neurosciences stock or one of its competitors? The main competitors of Jupiter Neurosciences include Adagene (ADAG), Pliant Therapeutics (PLRX), BioHarvest Sciences (BHST), Lexicon Pharmaceuticals (LXRX), Regulus Therapeutics (RGLS), Adlai Nortye (ANL), Rani Therapeutics (RANI), Anixa Biosciences (ANIX), Corbus Pharmaceuticals (CRBP), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical preparations" industry. Jupiter Neurosciences vs. Adagene Pliant Therapeutics BioHarvest Sciences Lexicon Pharmaceuticals Regulus Therapeutics Adlai Nortye Rani Therapeutics Anixa Biosciences Corbus Pharmaceuticals SELLAS Life Sciences Group Jupiter Neurosciences (NASDAQ:JUNS) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and community ranking. Does the MarketBeat Community believe in JUNS or ADAG? Adagene received 21 more outperform votes than Jupiter Neurosciences when rated by MarketBeat users. However, 100.00% of users gave Jupiter Neurosciences an outperform vote while only 78.57% of users gave Adagene an outperform vote. CompanyUnderperformOutperformJupiter NeurosciencesOutperform Votes1100.00% Underperform VotesNo VotesAdageneOutperform Votes2278.57% Underperform Votes621.43% Do insiders & institutionals believe in JUNS or ADAG? 9.5% of Adagene shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to JUNS or ADAG? In the previous week, Adagene had 5 more articles in the media than Jupiter Neurosciences. MarketBeat recorded 7 mentions for Adagene and 2 mentions for Jupiter Neurosciences. Jupiter Neurosciences' average media sentiment score of 0.94 beat Adagene's score of 0.66 indicating that Jupiter Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jupiter Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adagene 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer JUNS or ADAG? Adagene has a consensus price target of $8.00, suggesting a potential upside of 307.12%. Given Adagene's higher possible upside, analysts plainly believe Adagene is more favorable than Jupiter Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Adagene 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better earnings & valuation, JUNS or ADAG? Jupiter Neurosciences has higher earnings, but lower revenue than Adagene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJupiter NeurosciencesN/AN/AN/AN/AN/AAdagene$815.75K106.64-$18.95MN/AN/A Is JUNS or ADAG more profitable? Company Net Margins Return on Equity Return on Assets Jupiter NeurosciencesN/A N/A N/A Adagene N/A N/A N/A SummaryAdagene beats Jupiter Neurosciences on 7 of the 11 factors compared between the two stocks. Remove Ads Get Jupiter Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for JUNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JUNS vs. The Competition Export to ExcelMetricJupiter NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.60M$6.93B$5.63B$7.93BDividend YieldN/A2.72%4.89%4.05%P/E RatioN/A6.1123.6418.73Price / SalesN/A219.83371.04119.11Price / CashN/A65.6738.0534.64Price / BookN/A6.616.854.19Net IncomeN/A$139.99M$3.19B$247.07M Jupiter Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JUNSJupiter NeurosciencesN/A$0.59-6.5%N/AN/A$19.60MN/A0.005Analyst RevisionADAGAdagene2.6438 of 5 stars$1.99-2.0%$8.00+302.0%-33.7%$88.10M$815,746.000.00260Short Interest ↓News CoveragePLRXPliant Therapeutics4.603 of 5 stars$1.43-11.7%$13.31+830.9%-89.6%$87.57M$1.58M-0.4390High Trading VolumeBHSTBioHarvest SciencesN/A$5.33+0.2%$13.00+143.9%N/A$87.55M$22.43M-4.27N/AHigh Trading VolumeLXRXLexicon Pharmaceuticals2.7859 of 5 stars$0.35-9.5%$3.67+933.7%-84.9%$87.34M$5.23M-0.47140Earnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeRGLSRegulus Therapeutics2.5225 of 5 stars$1.33+3.1%$10.80+712.0%-37.3%$87.12MN/A-1.2430Upcoming EarningsNews CoverageGap DownANLAdlai Nortye1.8761 of 5 stars$2.33+0.9%$9.00+286.3%-72.9%$85.98M$5M0.00127Short Interest ↑RANIRani Therapeutics3.3785 of 5 stars$1.48-5.1%$12.33+733.3%-50.3%$84.79MN/A-1.40110Upcoming EarningsNews CoveragePositive NewsGap DownANIXAnixa Biosciences2.9293 of 5 stars$2.63-7.4%$8.50+223.2%-13.0%$84.68M$210,000.00-6.745Earnings ReportCRBPCorbus Pharmaceuticals3.77 of 5 stars$6.79flat$63.57+836.3%-84.5%$82.70MN/A-1.4540Earnings ReportAnalyst ForecastNews CoverageSLSSELLAS Life Sciences Group0.8989 of 5 stars$1.17-1.7%N/A-14.5%$82.35M$1M-1.7010Positive News Remove Ads Related Companies and Tools Related Companies ADAG Competitors PLRX Competitors BHST Competitors LXRX Competitors RGLS Competitors ANL Competitors RANI Competitors ANIX Competitors CRBP Competitors SLS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JUNS) was last updated on 3/13/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
